Cambridge Healthtech Institute’s 2nd Annual
Frontiers in Radiopharmaceutical Therapy
From Next-Gen Isotopes to Real-World Impact
May 12-13, 2026
In partnership with
Cambridge Healthtech Institute's 2nd annual Frontiers in Radiopharmaceutical Therapy conference spotlights the latest advances and clinical breakthroughs in radiolabelled therapies, with a special emphasis on emerging isotopes, dosimetry, combination treatments and next-generation platforms that are reshaping patient outcomes. Attendees can expect to explore new data from early preclinical and clinical trials, lessons learned in adaptive dosing and sequencing, innovative strategies and theranostic approaches targeting a spectrum of solid tumors. The conference will also highlight the regulatory perspectives and patient stratification tactics that are driving the field forward.
Coverage will include, but is not limited to:
PRECLINICAL AND EARLY CLINICAL DEVELOPMENT—EMERGING ISOTOPES AND NEXT-GENERATION RADIOTHERAPIES/THERANOSTICS
- Patient stratification and treatment sequence considerations
- Personalized antibody cocktails based on tumor profiling
- FAPI, GPC3, CXCR4, TROP2, DLL3 and other emerging targets
- Expanding indications beyond prostate cancer
CLINICAL ADVANCES AND LESSONS LEARNED
- Alpha vs. beta emitters: clinical data and selection criteria
- Novel isotopes: Ac-225, Pb-212, Lu-177 comparative analysis
- Theranostic approaches combining diagnostics and therapy
- Updates from PSMA, neuroendocrine, and colorectal cancer trials
DOSIMETRY, COMBINATION THERAPY, AND TREATMENT SEQUENCING
- Dosimetry optimization and personalized dosing strategies
- Adaptive dosing strategies using pharmacokinetic modeling
- Patient stratification and treatment sequence considerations
- Future considerations for optimal dosing
- Combining radiopharma with immunotherapy, CPIs, bispecifics, ADCs etc.
TARGETING MODALITIES & FORMATS
- Engineered antibodies, Fabs, DARPins, peptides vs small protein scaffolds
- Optimization for imaging vs. therapy applications
- Novel targeting approaches: PSMA, FAPI, neuroendocrine tumors
- Pretargeting Approaches
REGULATORY PERSPECTIVES
- Regulatory considerations from diagnostics, theranostics, and therapeutics perspectives
- FDA draft guidance and how it will impact trial design
The deadline for priority consideration is October 17, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: